[Remission of established disease in diabetic NOD mice induced by anti-CD3 monoclonal antibody].
Anti-CD3 monoclonal antibodies are potent immunosuppressants widely used in clinical transplantation to prevent or treat acute allograft rejection. We have used a hamster monoclonal antibody (145 2C11) specific for the epsilon chain of the murine CD3 complex to treat autoimmune insulin-dependent diabetes appearing spontaneously by 15 to 30 weeks of age in female Non Obese Diabetic (NOD) mice. Mice showing overt disease (glycosuria and glycemia > or = 4 g/l) were randomized in two groups receiving either anti-CD3 (5 micrograms/day i.v. for 5 consecutive days) or an identical dose of hamster polyclonal immunoglobulins. Progressive remission of disease was observed, 3 to 6 weeks after the end of treatment, in 80% of anti-CD3 treated mice as compared to 6% of mice in the control group. This remission was maintained long term namely, during the 4 to 5 months (after the end of treatment) observation period. These results open interesting perspectives on the possibility to treat recently diagnosed diabetic patients with therapy showing long term efficacy and no chronic toxicity.
Chatenoud
L
L
I.N.S.E.R.M. U n. 25, Hôpital Necker, Paris.
Thervet
E
E
Primo
J
J
Bach
J F
JF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D051379:Mice; D016688:Mice, Inbred NOD; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D016853:Muromonab-CD3
Rémission de la maladie établie chez la souris NOD diabétique par l'anticorps monoclonal anti-CD3.